Histone acetyltransferase p300 functions as a transcriptional co-activator which interacts with a number of transcription factors. Monocytic leukemia zinc finger protein (MOZ) has histone acetyltransferase activity. We report the fusion of the MOZ gene to the p300 gene in acute myeloid leukemia with translocation t(8;22)(p11;q13). FISH and Southern blot analyses showed the rearrangement of the MOZ and p300 genes. We determined the genomic structure of the p300 and the MOZ genes and the breakpoints of the translocation. Analysis of fusion transcripts indicated that the zinc finger and acetyltransferase domains of MOZ are fused to a largely intact p300. These results suggest that MOZ-p300, which has two acetyltransferase domains, could be involved in leukemogenesis through aberrant regulation of histone acetylation. Leukemia (2001) 15, 89-94.
Introduction
DNA is associated with histone and non-histone proteins to form nucleosomes and higher order structures in eukaryotes. The amino termini of histones can be modified by acetylation. Acetylation of specific residues of the histones is associated with gene activity and may play a fundamental role in transcriptional regulation. 1 The level and state of histone acetylation are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). Some HATs and HDACs interact with specific DNA-binding transcription activator and repressor proteins, which strongly suggests that they modulate transcriptional activity of specific promoters by regulating local histone acetylation. [1] [2] [3] [4] Acetylation of histones neutralizes the positively charged lysine residues of the histone N-termini, which decreases their affinity for DNA. This results in unfolding of nucleosomes and increases access for transcription factors. Recently, it was reported that bromodomains, motifs found in several eukaryotic transcription factors, specifically interact with acetyl-lysines in histones H3 and H4. 5 This finding suggests that bromodomain-containing proteins may be involved in the regulatory effects of histone acetylation by binding to acetyl-lysines. p300 and CREB-binding protein (CBP) were initially identified as cellular proteins which bind to the adenovirus-E1a oncoprotein and transcription factor CREB, respectively. 6,7 p300/CBP are functionally conserved transcriptional coactivators for a large number of transcription factors and have intrinsic acetyltransferase activity. 8 MOZ was identified as the gene that is located at the breakpoint of the t(8;16) chromosome translocation found in acute myeloid leukemia (AML). 9 Although MOZ has the MYST domain, part of which is homologous to several prokaryotic and eukaryotic acetyltransferases, 9 it has not yet been reported if MOZ has acetyltransferase activity.
Specific chromosome translocations frequently found in human leukemia involve rearrangements of genes which are implicated in the regulation of hematopoiesis. The chromosome translocations often result in the expression of fusion gene products. Certain genes which encode proteins with HAT activity or potential HAT activity, such as the monocytic leukemia zinc finger protein (MOZ), CREB-binding protein (CBP), p300 and TIF2, are targets of translocations found in AML, myelodysplastic syndrome (MDS) and acute mixed lineage leukemia. [9] [10] [11] [12] [13] [14] [15] The MOZ gene was shown to be fused to the CBP gene and the TIF2 gene in the translocation t(8;16) and inv (8) , respectively. [9] [10] [11] We have found that p300 forms a fusion protein with MLL through the t(11;22) translocation in AML. 12 The t(8;22)(p11;q13) is found in rare cases of AML. 16, 17 The breakpoints of the translocation on chromosomes 8 and 22 correspond to the MOZ and p300 loci, respectively. In addition, features of this subgroup of AML, including monocytic arrest and erythrophagocytosis resemble those of classical AML with t(8;16)(p11.2; p13.3), in which MOZ is fused to CBP. We report here a novel fusion of MOZ to p300 in AML with t(8;22)(p11.2;q13.1). We will discuss roles of the resultant MOZ-p300 fusion histone acetyltransferase.
Materials and methods

Patient
A 55-year-old man was initially diagnosed as having primary macroglobulinemia. He developed secondary AML during chemotherapy which included melpharan, vincristine, cyclophosphamide, procarbazine, adriamycin and MCNU. The patient presented with monocytic arrest and an increased level of erythrophagocytosis. Cytogenetic study of bone marrow cells showed the karyotype 47, XY, t(8;22)(p11.2;q13.1), +der (8) 
Isolation of genomic MOZ and p300 clones
P1 and PAC clones containing MOZ or p300 were isolated by polymerase chain reaction (PCR) screening of human P1 or PAC libraries using the following primers: 5Ј-TCGGCGAATTTGTGCTCTTG-3Ј and 5Ј-GGGGAAGTT CCTTTTTCTCTTCG-3Ј for p300 PAC827K2, 5Ј-TTCTTCC CCTTTGTGTGTGTGG-3Ј and 5Ј-AACCCCTTTTGTCCTCT GGTTTAG-3Ј for p300 P1-8C1, 5Ј-CCCCAGTGATTTGCC TCTTAGG-3Ј and 5Ј-GGTCTGTCCCTCTTCTCATTAGCC-3Ј for MOZ P1-56F7.
Leukemia
Figure 1
FISH analysis of leukemic metaphase chromosomes with t(8;22)(p11;q13). Hybridizations were performed using the PAC827K2 probe, specific to the p300 gene and the D8Z1 probe specific to the centromere of chromosome 8. The derivative chromosomes der(8) and der(22) as well as normal chromosomes 8 and 22 are indicated. Signals were observed on der(8), +der(8) and der(22) as well as on normal chromosome 22 (arrows). Chromosomes were counterstained with DAPI.
Fluorescence in situ hybridization (FISH) analysis
FISH analyses were performed on a metaphase sample, which was used for a cytogenetic, as described previously 12 by using the following probes: p300 PAC827K2, p300 P1-8C1 and the ␣ satellite probe specific to the centromere of chromosome 8 (D8Z1; Oncor, Gaithersburg, MD, USA). All probes were labeled with digoxigenin-11-dUTP, and were detected with antidigoxigenin-rhodamin (Boehringer Mannhein, Mannheim, Germany).
Southern blot analysis
Southern blot analyses were performed as described previously 12 using the following probes: p300 probe A, a 595-bp fragment containing p300 exon 3 generated by PCR using the following primers; 5Ј-CTTTGTGAACTTGGAAGTGAAATC-3Ј and 5Ј-CCCAAAAGTGAAAGGTTCCG-3Ј; and MOZ probe B, an 8.5-kb BamHI fragment containing MOZ exons 10-14.
Genomic structures and restriction maps of the MOZ and p300 genes
DNA from the clones p300 PAC827K2 and MOZ P1-56F7 was digested with BamHI, EcoRI and NotI and subjected to Southern blot analysis using each of the BamHI fragments and respective cDNAs as probes. Boundaries between exons and introns were determined by their sequence analyses using primers based on cDNA sequences. 6, 9 The lengths of the introns were determined by PCR analyses using primers based on the determined sequences of the exon/intron boundaries or vector sequences.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Reverse transcription of 1 g of total RNA was done using random hexamers according to the manufacturer's protocol (GIBCO BRL, Gaithersburg, MD, USA). One l of the RT-mixture was amplified by PCR using the following primers as follows: p300 P1, 5Ј-AACAGAAGGAAGTGAGAGGCTGC-3Ј and MOZ P6, 5Ј-TATGT GCTCCAGAACCCATCCC-3Ј; p300 P2, 5Ј-TACAGTGAG GGTGACAGGGCTG-3Ј and MOZ P5, 5Ј-TGTCTGAATC TGGAGACCAAGGC-3Ј; MOZ P3, 5Ј-CTCGGAGTCAGAATCTTCAAAAGG-3Ј and p300 P4 5Ј-GATATGCAGTACCCAAACCCAGG-3Ј.
Results and discussion
Similarities in phenotypic features between AMLs with t(8;16) and t(8;22) and the loci of the breakpoints suggest that MOZ and p300 may be involved in the t(8;22)(p11.2; q13.1), as this hypothesis has been suggested. 9 To determine if p300 is involved in this translocation, FISH analyses were performed using human genomic DNA clones spanning the p300 genes. The clone containing the 5Ј end of the coding region of the p300 gene (PAC827K2) hybridized to both der(8) and der(22) as well as to normal chromosome 22 in metaphase chromo-somes from the leukemic cells (Figure 1) . However, the clone containing the 3Ј-region of the p300 gene (P1-8C1) hybridized to der(8) and normal chromosome 22 but not to der(22) (data not shown). These results suggest that the p300 gene is disrupted in t(8;22), and that the breakpoint is located in the 5Ј region of the p300 gene. To determine the breakpoint in the p300 gene, we performed Southern blot analysis using fragments of the PAC827K2 clone as probes (see Figure 2b) . Using a fragment containing exon3 (probe A), we detected an 11-kb aberrant band as well as a 2.8-kb germline band, suggesting that the breakpoint on chromosome 22 is located in the 2.8-kb region of the p300 gene (Figure 3) .
Southern blot analysis using full-length MOZ cDNA as a probe detected an 11-kb aberrant band (data not shown). To 18 and the breakpoints identified in this study, respectively. BamHI (B), NotI (N), and EcoRI (E) sites are indicated.
Leukemia confirm this and determine the breakpoint on chromosome 8, Southern blot analyses were performed using several DNA fragments of the P1-56F7 clone which contained the 3Ј-region of the MOZ gene (Figure 2a ). An 8.5-kb BamHI fragment which contains five exons (11) (12) (13) (14) (15) spanning nucleotides 2134 to 3432 (corresponding to the MYST domain and the acidic domain of MOZ), was used as a probe and detected a rearranged 11-kb band as well as a 8.5-kb germline band (Figure 3) . These results suggest that the breakpoint on chromosome 8 is located in the 8.5-kb region of the MOZ gene.
The FISH and Southern blot analyses suggested that the translocation t(8;22) results in a fusion between the MOZ gene and the p300 gene. To test whether the MOZ-p300 and p300-MOZ fusion transcripts are expressed in the leukemic cells,
Figure 3
Rearrangement of the MOZ gene and the p300 gene. Genomic DNAs from leukemic cells of the AML patient with t(8;22) (P) and control normal cells (N) were digested with BamHI and analyzed by Southern blot hybridization using the p300 probe A and MOZ probe B as described in Figure 2 . Arrows indicate positions of the rearranged fragments.
RT-PCR analysis was performed. Using a sense primers to MOZ exon 15 (P1) and an antisense primer (P6) to p300 exon 4, we obtained a PCR product of 410 bp (Figure 4a) . Furthermore, using inner sets of primers (sense primer, P2 to MOZ exon 15; antisense primer, P5 to p300 exon 3), we amplified a fragment of expected size (222 bp) (Figure 4a ). Sequence analysis of the amplified fragments revealed that exon 15 of the MOZ gene was juxtaposed to exon 3 of the p300 gene with an in-frame junction ( Figure 5 ). The reciprocal PCR product of the p300-MOZ fusion transcript was detected by an RT-PCR assay using a sense primer to p300 exon 2 (P4) and an antisense primer to MOZ exon 15 (P3) (Figure 4b) . The sequence analysis of the PCR product showed that p300 exon 2 was fused to MOZ exon 16 with an in-frame junction ( Figure 5) .
We have shown that the MOZ gene is fused to the p300 gene in AML with t(8;22)(p11;q13). Both MOZ-p300 and p300-MOZ fusion transcripts are expressed in the AML cells. A schematic representation of the predicted fusion proteins is shown in Figure 5 . The MOZ-p300 fusion protein, which con-
Figure 4
Expression of MOZ-p300 and p300-MOZ fusion transcripts. (a) Detection of MOZ-p300 transcripts. RT-PCR analysis was preformed using RNAs from leukemic cells of the AML patient with t(8;22). The PCR primers are MOZ P1 and p300 P6 (lane 1), and MOZ P2 and p300 P5 (lane 2). The PCR products were excised and used as templates for the second round of amplification using primers, MOZ P2 and p300 P5 (lane 3). (b) Detection of p300-MOZ transcripts. RT-PCR analysis was preformed using primers, p300 P4 and MOZ P3.
sists of 3184 amino acids, is similar to MOZ-CBP. MOZ-p300 retains the PHD-type zinc finger, the MYST domain and a part of the acidic region of MOZ, which is fused to a largely intact p300. On the other hand, the reciprocal p300-MOZ chimeric protein retains the nuclear receptor interaction domain (NID) of p300, which is fused to a C-terminal portion of the acidic, serine-rich, proline/glutamine-rich and methionine-rich regions of MOZ. During preparation of this paper, Chaffanet et al 18 reported that MOZ-p300 fusion transcripts were expressed in t(8;22)(p11;q13). The breakpoints they identified, as well as others such as t(8;16) and t (11;22) , which result in rearrangements in MOZ or p300, were distinct from the ones found in this study. Figure 2a shows the genomic structures of the MOZ gene and the p300 gene and the breakpoints of the translocations. The breakpoints in the MOZ gene are found in introns 15-18. The breakpoints of t (8;22) shown in the present study are in the most proximal region corresponding to the N-terminal end of the acidic region, suggesting that a large part of the acidic region, all of which is retained in the MOZ-CBP fusion protein resulting from t(8;16), might be dispensable for the function of MOZ-p300 and possibly MOZ-CBP. We have found that MOZ shows histone acetyltransferase activity and that the region corresponding to exons 9-14 is essential and sufficient for activity (unpublished data). Since all of the breakpoints found in leukemia are located in introns 15-18 of the MOZ gene, the variety of resulting chimeric proteins such as MOZ-CBP, MOZ-p300 and MOZ-TIF2 all retain the intact HAT domain of MOZ. These results suggest that the HAT domain might be important for the function of the MOZcontaining chimeric proteins in leukemogenesis. On the other hand, the breakpoints on p300 are widely distributed and found in introns 1, 2 and 11. However, resultant chimeric proteins such as MLL-p300 and MOZ-p300 retain the catalytic domain of p300 for HAT 8 similar to MLL-CBP and MOZ-CBP. In the case of the MOZ-containing chimeric proteins, the HAT domains of both proteins are retained. Taken together, this 18 and the breakpoints identified in this study, respectively. NID, nuclear receptor interaction domain; CH1-3, cysteine/histidine-rich domain; CID, CREB-interaction domain; Br, bromodomain; HAT, histone acetyltransferase domain; Q, glutamine-rich region; PHD, PHD class zinc finger; MYST, MOZ, YB1, SAS, TIP homology domain; S, serine-rich region; PQ, proline/glutamine region; M, methionine-rich region. consistent preservation of HAT domains during a variety of translocations, producing fusion proteins which have two catalytic domains may result in abnormal regulation of histone acetylation. This and the subsequent alterations to gene expression are possibly important steps in leukemogenesis. We previously found that p300/CBP function as co-activators for AML1 which is the most frequent target of chromosomal rearrangements in human leukemia and encodes a transcription factor which is essential for definitive hematopoiesis.
